Abstract
Purpose :
To compare endophthalmitis rates in anterior segment surgery with and without the use of intracameral vigamox using a retrospective case study.
Methods :
Anterior segment surgery logs from January 2018 to July 2022 were pulled from a high volume ambulatory surgery center (ASC) and segregated based on surgeon, intracameral vigamox use, and development of endophthalmitis. The data were analyzed using a student t-test for significance with a p-value of 0.005.
Results :
A total of 17,057 anterior segment cases (all modern cataract surgeries) were reviewed. Of these, 13,594 cases had intracameral vigamox used at the end of the case. 3,463 cases did not. 5 cases (0.037%) with intracameral vigamox developed endophthalmitis. 5 cases (0.14%) without intracameral vigamox developed endophthalmitis. A two-tailed student’s t-test found this to be a statistically significant difference (0.0025).
Conclusions :
The results of this study reaffirm what prior studies have shown regarding intracameral vigamox use at the conclusion of modern cataract surgery. There was a statistically significant decrease in the cases of endophthalmitis when intracameral vigamox was used. Further study is needed to verify visual outcomes.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.